Literature DB >> 32972546

Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies.

Eoin Donnellan1, Oussama M Wazni1, Mazen Hanna1, Mohamed B Elshazly1, Rishi Puri1, Walid Saliba1, Mohamed Kanj1, Sneha Vakamudi1, Divyang R Patel1, Bryan Baranowski1, Daniel Cantillon1, Thomas Dresing1, Wael A Jaber2.   

Abstract

OBJECTIVES: This study sought to determine the incidence and prevalence of atrial fibrillation (AF) in transthyretin cardiac amyloidosis (ATTR-CA); to study the factors associated with the development of AF in this population; to study the prognostic implications of AF and maintenance of normal sinus rhythm (NSR) in patients with ATTR-CA; and to determine the impact of ATTR-CA stage on AF prevalence, outcomes, and efficacy of rhythm control strategies.
BACKGROUND: AF is common in patients with ATTR-CA. The aim of this study was to determine the predictors, prevalence, and outcomes of AF in patients with ATTR-CA in addition to the efficacy of rhythm control strategies.
METHODS: This was a retrospective cohort study of 382 patients with ATTR-CA diagnosed at our institution between January 2004 and January 2018. Means testing, and univariable and multivariable models were used.
RESULTS: AF occurred in 265 (69%) patients. Factors associated with the development of AF included older age, advanced ATTR-CA stage, and higher left atrial volume index. Antiarrhythmic therapy (AAT) was used in 35% of patients with AF; cardioversion was performed in 45%, and 5% underwent AF ablation. Rhythm control strategies were substantially more effective when performed earlier in the disease course. During a mean follow-up of 35 months, no difference in mortality between patients with AF and those without AF was observed (65% vs. 49%; p = 0.76). On Cox proportional hazards analyses, maintenance of normal sinus rhythm and tafamidis use were associated with improved survival, whereas advanced ATTR-CA stage and higher New York Heart Association functional class were associated with increased mortality.
CONCLUSIONS: With advancing ATTR-CA stage, AF became more prevalent, occurring in 69% of our entire study cohort. Rhythm control strategies including AAT, direct-current cardioversion, and AF ablation were substantially more effective when performed earlier during the disease course.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; heart failure; rhythm control; transthyretin amyloid

Year:  2020        PMID: 32972546     DOI: 10.1016/j.jacep.2020.04.019

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  11 in total

Review 1.  Clinical management of amyloid cardiomyopathy.

Authors:  Morris M Kim; Clinton M Kolseth; Dayna Carlson; Ahmad Masri
Journal:  Heart Fail Rev       Date:  2021-09-01       Impact factor: 4.654

Review 2.  Comprehensive approach to cardiac amyloidosis care: considerations in starting an amyloidosis program.

Authors:  Brett W Sperry; Julie A Khoury; Shahzad Raza; Julie L Rosenthal
Journal:  Heart Fail Rev       Date:  2021-08-30       Impact factor: 4.654

Review 3.  Thromboembolism and bleeding in systemic amyloidosis: a review.

Authors:  Martin Nicol; Virginie Siguret; Giuseppe Vergaro; Alberto Aimo; Michele Emdin; Jean Guillaume Dillinger; Mathilde Baudet; Alain Cohen-Solal; Camille Villesuzanne; Stephanie Harel; Bruno Royer; Bertrand Arnulf; Damien Logeart
Journal:  ESC Heart Fail       Date:  2021-11-16

4.  Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.

Authors:  Cassady Palmer; Vien T Truong; Jeremy A Slivnick; Sarah Wolking; Paige Coleman; Wojciech Mazur; Karolina M Zareba
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

5.  Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias.

Authors:  Yoshitaka Isotani; Eisuke Amiya; Junichi Ishida; Masato Ishizuka; Masaru Hatano; Koki Nakanishi; Masao Daimon; Issei Komuro
Journal:  Oxf Med Case Reports       Date:  2022-02-19

6.  Clinical, Laboratory, and Imaging Profile in Patients with Systemic Amyloidosis in a Brazilian Cardiology Referral Center.

Authors:  Fábio Fernandes; Aristóteles Comte de Alencar Neto; Bruno Vaz Kerges Bueno; Caio Rebouças Fonseca Cafezeiro; João Henrique Rissato; Roberta Shcolnik Szor; Mariana Lombardi Peres de Carvalho; Wilson Mathias Júnior; Angelina Maria Martins Lino; Jussara Bianchi Castelli; Evandro de Oliveira Souza; Félix José Alvarez Ramires; Viviane Tiemi Hotta; José Soares Júnior; Caio de Assis Moura Tavares; José Eduardo Krieger; Carlos Eduardo Rochitte; André Dabarian; Ludhmila Abrahão Hajjar; Roberto Kalil Filho; Charles Mady
Journal:  Arq Bras Cardiol       Date:  2022-02       Impact factor: 2.000

7.  Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients.

Authors:  Mathijs O Versteylen; Maaike Brons; Arco J Teske; Marish I F J Oerlemans
Journal:  Biomedicines       Date:  2022-07-22

Review 8.  Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.

Authors:  Weiqin Lin; Pairoj Chattranukulchai; Alex Pw Lee; Yen-Hung Lin; Wen-Chung Yu; Houng-Bang Liew; Abraham Oomman
Journal:  Clin Cardiol       Date:  2022-07-06       Impact factor: 3.287

Review 9.  ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Jan M Griffin; Julie L Rosenthal; Justin L Grodin; Mathew S Maurer; Martha Grogan; Richard K Cheng
Journal:  JACC CardioOncol       Date:  2021-10-19

Review 10.  Echocardiographic Assessment of Atrial Function: From Basic Mechanics to Specific Cardiac Diseases.

Authors:  Katsuji Inoue; Hiroshi Kawakami; Yusuke Akazawa; Haruhiko Higashi; Takashi Higaki; Osamu Yamaguchi
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.